As weight loss medications like Ozempic continue to gain popular, experts and patients are noticing varying effects of the ...

Key players like Novo Nordisk lead the market, which is influenced by patent protection and competitive dynamics in drug ... Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

There is no public data available about the revenues and market size for compounding ... since the company already has Rybelsus, a prior-generation semaglutide pill, on the market.

Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects. The ...

The new data follows another study that showed the effectiveness of Wegovy could be stepped up by raising the weekly dose of the drug. The size of the ... therapy called Rybelsus have been ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Rybelsus is a prescription drug that’s used to manage type 2 diabetes. Rybelsus comes as tablets that you swallow. You’ll take Rybelsus by mouth once per day, at least 30 minutes before your ...